Purchase this article with an account.
T. W. Wiegand, A. H. Rogers, P. Yates, E. Reichel, J. S. Duker; Intravitreal Injection of Bevacizumab (Avastin) for Choroidal Neovascularization Caused by Angioid Streaks. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3396.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin) as treatment for choroidal neovasculariztion (CNV) in patients with angioid streaks.
A non-randomized, interventional case series was conducted on eyes with subfoveal CNV associated with angioid streaks. Intravitreal bevacizumab (1.25 mg in 0.05 ml) was injected into five eyes of three patients between August 2005 and December 2006. Treatment efficacy was assessed by comparing pre- and post-treatment visual acuity and optical coherence tomography (OCT) images.
Best corrected visual acuity improved two or more lines in 1 eye (20%) and remained within one line of pre-treatment visual acuity in 4 eyes (80%). No patient lost two or more lines in the duration of the study period. Follow-up extended from 2 to 16 months and pre-treatment visual acuities ranged from 20/20 to 20/100. OCT analysis was performed prior to each treatment and at 4-6 week follow-up visits. Central foveal thickness showed an average decrease of 15 microns on post- injection visits compared to an average increase of 25 microns between visits without injection (p=0.031). Retreatments were performed in 3 eyes (60%). No injection-related complications or drug-related side effects were observed.
Intravitreal bevacizumab for the treatment of CNV associated with angioid streaks led to a reduction in macular thickness on OCT with stabilization of visual acuity. The treatment was safe and well-tolerated by all patients. Longer follow-up and a larger patient cohort are needed to further evaluate the long-term efficacy of this treatment.
This PDF is available to Subscribers Only